GTS Securities’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-73,600
Closed -$6.17M 2364
2024
Q3
$6.17M Buy
73,600
+2,400
+3% +$183K 0.01% 756
2024
Q2
$4.89M Buy
71,200
+35,000
+97% +$2.34M 0.01% 875
2024
Q1
$2.65M Sell
36,200
-37,400
-51% -$2.88M ﹤0.01% 1287
2023
Q4
$5.96M Sell
73,600
-39,600
-35% -$3.08M 0.01% 888
2023
Q3
$8.48M Buy
+113,200
New +$8.71M 0.02% 670

Other funds holding GILD

GTS Securities's GILD Position: Q2 2026 in Review

GTS Securities reduced its Gilead Sciences (GILD) stake by 35% in Q2 2026, selling an estimated $325K and leaving 4,608 shares worth $582K. The position accounts for 0.01% of the portfolio, ranked #646.

GTS Securities first reported a position in GILD in Q2 2023 and has held it in 13 quarters since. The position peaked at $8.51M in Q3 2023. 2,285 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • GTS Securities held 4,608 shares of Gilead Sciences worth $582K as of Q2 2026.
  • GTS Securities sold 2,469 Gilead Sciences shares in Q2 2026, an estimated $325K.
  • Gilead Sciences made up 0.01% of GTS Securities's portfolio in Q2 2026, its #646 holding.
  • GTS Securities first reported a position in Gilead Sciences in Q2 2023 and has held it in 13 quarters since.
  • GTS Securities's Gilead Sciences position peaked at $8.51M in Q3 2023.
  • 2,285 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.